Neurovisual impairment: A frequent complication of alpha-interferon treatment in chronic viral hepatitis

Hepatology

Volumn 27, Issue 5, 1998, Pages 1421-1427

  Manesis, Emanuel K ^a   Moschos, Michael ^a   Brouzas, Dimitrios ^a   Kotsiras, John ^a   Petrou, Constantine ^a   Theodosiadis, George ^a   Hadziyannis, Stephanos ^a,b  

^a IASO GENERAL HOSPITAL   (Greece)

^b HIPPOKRATION HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; RECOMBINANT ALPHA2B INTERFERON;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; ELECTRORETINOGRAM; EVOKED VISUAL RESPONSE; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; OPHTHALMOSCOPY; OPTIC NERVE DISEASE; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; VISUAL ACUITY; VISUAL FIELD; VISUAL IMPAIRMENT;

ADULT; AGED; EVOKED POTENTIALS; FEMALE; HEPATITIS B; HEPATITIS C; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETINA; VISION DISORDERS; VISUAL FIELDS;

EID: 0031959793     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510270533     Document Type: Article

References (33)

1. Ene L, Gehenot M, Detry-Morel M, Geubel AP. Transient blurred vision after interferon for chronic hepatitis C [Letter]. Lancet 1994;344:827-828.
2. Kuga K, Hasumura S, Nagamori S, Toda G, Kitahara K. Intraocular hemorrhage developing during interferon therapy. Intern Med 1996;35: 15-18.
3. Ayaki M. Development of neovascular glaucoma in the course of interferon alfa therapy for hepatitis type C [Letter]. Br J Ophthalmol 1994;78:238.
4. Purvin VA. Anterior ischemic optic neuropathy secondary to interferon alfa. Arch Ophthalmol 1995;113:1041-1044.
5. Okanoue T, Sakamoto S, Itoh Y, Minami M, Yasui K, Sakamoto M, Nishioji K, et al. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 1996;25:283-291.
6. Farkkila M, Iivanainen M, Roine R, Bergstrom L, Laaksonen R, Niemi ML, Cantell K. Neurotoxic and other side effects of high-dose interferon in amyotrophic lateral sclerosis. Acta Neurol Scand 1984;70:42-46.
7. Yamanda H, Mizobuchi K, Isogai Y. Acute onset of ocular complications with interferon [Letter]. Lancet 1994;343:914.
8. Guyer DR, Tiedeman J, Yannuzzi LA, Slakter JS, Parke D, Kelly J, Tang RA, et al. Interferon-associated retinopathy. Arch Opthalmol 1993;111: 350-356.
9. Sugano S, Yanagimoto M, Suzuki T, Sato M, Onmura H, Aizawa H, Makino, et al. Retinal complications with elevated circulating plasma C5a associated with interferon-alpha therapy for chronic active hepatitis C. Am J Gastroenterol 1994;89:2054-2056.
10. Hayasaka S, Fujii M, Yamamoto Y, Noda S, Kurome H, Sasaki M. Retinopathy and subconjunctival haemorrhage in patients with chronic viral hepatitis receiving interferon alfa. Br J Ophthalmol 1995;79:150-152.
11. Soushi S, Kobajashi SS, Obazawa H, Kigasawa K, Shiraishi K, Itakura M, Matsuzaki S. Evaluation of risk factors of interferon-associated retinopathy in patients with type C chronic active hepatitis. Nippon Ganka Gakkai Zasshi 1996;100:69-76.
12. Kawano T, Shigehira M, Uto H, Nakama T, Kato J, Hayashi K, Maruyama T, et al. Retinal complications during interferon therapy for chronic hepatitis C. Am J Gastroenterol 1996;91:309-313.
13. Manesis EK, Petrou K, Brouzas D, Hadziyannis S. Optic tract neuropathy complicating low-dose interferon treatment. J Hepatol 1994;21:474-477.
14. American Electroencephalographic Society. Guidelines for clinical evoked potential studies. J Clin Neurophysiol 1984;1:3-53.
15. Chiapa KH, Gill EM, Lentz KE. The effect of check size on P100 latency. Electroencephalogr Clin Neurophysiol 1985;61:29P-30P.
16. Aderson DR. Perimetry with and without automation. Mosby Co, St Louis, Ed. 2. 1987.
17. Kanski JJ. Hypertensive retinopathy. In: Clinical Ophthalmology. Ed. 2. A Systematic Approach. London: Butterworths, 1989:328-330.
18. Klein R, Klein BEK. Diabetic eye disease. Lancet 1997:350:197-204.
19. Kertes PJ, Britton WA Jr, Addison DJ, Munro SM, Marshall DH, Leonard BC. Toxicity of intravitreal interferon alpha-2b in the rabbit. Can J Ophthalmol 1995;30:355-359.
20. Woung LC, Jou JR, Liaw SL. Visual function in recovered ethambutol optic neuropathy. J Ocul Pharmacol Ther 1995;11:411-419.
21. Weissenborn K, Scholz M, Hinrichs H, Wiltfang J, Schmidt FW, Kunkel H. Neurophysiological assessment of early hepatic encephalopathy. Electroencephalogr Clin Neurophysiol 1990;75:289-295.
22. Halliday AM, McDonald WI, Mushin J. Delayed visual evoked response in optic neuritis. Lancet 1972;1:982-985.
23. Tilg H. New insights into the mechanisms of interferon alfa: an immunoregulatory and anti-inflammatory cytokine. 1997;112:1017-1021.
24. Fleet WS, Watson RT. Autoimmune optic neuritis: a potentially treatable form of visual loss. Ann Ophthalmol 1986;18:144-146.
25. Kupersmith MJ, Burde RM, Warren FA, Klingele TG, Frohman LP, Mitnick H. Autoimmune optic neuropathy: evaluation and treatment. J Neurol Neurosurg Psychiatr 1988;51:1381-1386.
26. Miller J, Stinson WG, Folkman J. Regression of experimental iris neovascularization with systemic alpha-interferon. Ophthalmology 1993; 100:0-14.
27. Abrams DI, Volberding PA. Alpha interferon therapy of AIDS-associated Kaposi's sarcoma. Semin Oncol 1986;13:43-47.
28. White CW, Sonbeimer HM, Crouch EC, Wilson H, Fan LL. Treatment of pulmonary hemangiomatosis with recombinant interferon alfa-2a. N Engl J Med 1989;320:1197-1200.
29. Hadziyannis SJ. The spectrum of extrahepatic manifestations of hepatitis C virus infection. J Vir Hep 1997;4:9-28.
30. Lisker-Melman M, Webb D, Di Bisceglie AM, Kassianidis C, Martin P, Rustgi V, Waggoner JG, et al. Glomerulonephritis caused by chronic hepatitis B virus infection: treatment with recombinant human alpha-interferon. Ann Intern Med 1989;111:479-483.
31. Galli M, Morelli R, Casellato A, Perna MC. Retrobulbar optic neuritis in a patient with acute type B hepatitis. J Neurol Sci 1986;72:195-200.
32. Levy LJ, Bolton RP, Losowsky MS. The use of the visual evoked potential (VHP) in delineating a state of subclinical hepatic encephalopathy. A comparison with the number connection test. J Hepatol 1987;5:211-217.
33. Quero JC, Schalm SW. Subclinical hepatic encephalopathy. Semin Liver Dis 1996;16:321-328.